ATE214160T1 - Überwachung der immunotherapie von malignen tumoren - Google Patents

Überwachung der immunotherapie von malignen tumoren

Info

Publication number
ATE214160T1
ATE214160T1 AT96919761T AT96919761T ATE214160T1 AT E214160 T1 ATE214160 T1 AT E214160T1 AT 96919761 T AT96919761 T AT 96919761T AT 96919761 T AT96919761 T AT 96919761T AT E214160 T1 ATE214160 T1 AT E214160T1
Authority
AT
Austria
Prior art keywords
cells
proliferation
drug
malignant tumors
culture
Prior art date
Application number
AT96919761T
Other languages
English (en)
Inventor
Leif Hakansson
Original Assignee
Landstinget I Oestergoetland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landstinget I Oestergoetland filed Critical Landstinget I Oestergoetland
Application granted granted Critical
Publication of ATE214160T1 publication Critical patent/ATE214160T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96919761T 1995-05-12 1996-05-10 Überwachung der immunotherapie von malignen tumoren ATE214160T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501780A SE9501780D0 (sv) 1995-05-12 1995-05-12 Monitoring immunotherapy of malignant tumours
PCT/EP1996/002006 WO1996035948A1 (en) 1995-05-12 1996-05-10 Monitoring immunotherapy of malignant tumours

Publications (1)

Publication Number Publication Date
ATE214160T1 true ATE214160T1 (de) 2002-03-15

Family

ID=20398297

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919761T ATE214160T1 (de) 1995-05-12 1996-05-10 Überwachung der immunotherapie von malignen tumoren

Country Status (8)

Country Link
US (1) US6242202B1 (de)
EP (1) EP0824695B1 (de)
JP (1) JP3537826B2 (de)
AT (1) ATE214160T1 (de)
CA (1) CA2215630A1 (de)
DE (1) DE69619667T2 (de)
SE (1) SE9501780D0 (de)
WO (1) WO1996035948A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3782958D1 (de) * 1986-02-19 1993-01-21 Imreg Inc Verfahren und mittel zum pruefen eines immunsystems.

Also Published As

Publication number Publication date
WO1996035948A1 (en) 1996-11-14
SE9501780D0 (sv) 1995-05-12
EP0824695A1 (de) 1998-02-25
JP3537826B2 (ja) 2004-06-14
US6242202B1 (en) 2001-06-05
DE69619667T2 (de) 2002-10-31
EP0824695B1 (de) 2002-03-06
CA2215630A1 (en) 1996-11-14
DE69619667D1 (de) 2002-04-11
JPH11504714A (ja) 1999-04-27

Similar Documents

Publication Publication Date Title
Gu et al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
WO2003106692A3 (en) Methods for the identification of all-antigens and their use for cancer therapy and transplantation
DE69519796D1 (de) PTPalpha-Bestimmung in der Tumordiagnose und -Prognose
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
BR0312534A (pt) método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
NO904001L (no) Fremgangsmaate og apparat, for diagnostisk analyse.
US12411130B2 (en) Methods of assessing protein interactions between cells
EP1102988B8 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
Davern et al. Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients
Xie et al. Complement‐activated human endothelial cells stimulate increased polyfunctionality in alloreactive T cells
ATE214160T1 (de) Überwachung der immunotherapie von malignen tumoren
DK0824696T3 (da) Fremgangsmåde og kit til at forudsige den terapeutiske reaktion på et medikament mod en malign tumor
Jandová et al. Effects of sinusoidal magnetic field on adherence inhibition of leukocytes
WO2004041076A3 (en) Methods of detecting colorectal cancer
Wischermann et al. Improved alkaline comet assay protocol for adherent HaCaT keratinocytes to study UVA-induced DNA damage
EP3942297A2 (de) Verfahren und systeme zur auswertung von zellproben
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
CA2264963A1 (en) Protein markers for esophageal cancer
DE69839846D1 (de) Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten
DE69713094D1 (de) Verfahren zur erkennung von malignen transformierten menschlichen zellen
Beztsinna et al. Immunotherapy testing in 3D Ex vivo Patient Tissue Platform with preserved tumor microenvironment
AU3986697A (en) Use of molt4 cd69 expression to determine the presence and activity of interferon inhibitors
Inozume et al. 774 Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost MHC class I expression after anti-PD-1 therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties